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Intensive Chemotherapy and Bone Marrow Transplantation 
for Myelodysplastic Syndromes
Winfried Gassmarm, Norbert Schmitz, Helmut Löffler, and Theo De Witte
CUTE MYELOGENOUS LEUKEMIAS 
(AMLs) and myelodysplastic syndromes 
(MDSs) are considered to differ with regard to 
response rate and remission duration after 
chemotherapy. Patients suffering from AML 
can be cured by conventional chemotherapy 
whereas those with MDS are considered incur­
able.
Therapy for MDS using low-dose cytostatic 
agents, growth factors, or substances aimed at 
differentiation induction is capable of prolong­
ing survival and improving quality of life.44 
Long-term benefit, however, can only be 
achieved by eradication of the abnormal clone 
and restoration of normal hematopoiesis. 
Whether this can be accomplished using inten­
sive chemotherapy or the transplantation of 
hematopoietic stem cells is discussed in this 
article.
AML-TYPE CHEMOTHERAPY FOR MDS
i
Treatment of MDSs with AML-type chemo­
therapeutic regimens is capable of inducing 
complete remission (CR). This was shown in 
the early 1980s by Armitage et al6 and Mertels- 
mann et al47 who reported CR rates of 15% and 
45%, respectively. Later, these data were con­
firmed by other groups using various combina­
tions of cytostatic agents.
Most groups have used daunorubicin com­
bined with conventional or high-dose cytosine 
arabinoside (Ara-C)63 or regimens adding thio- 
guanine.43 Furthermore, combinations of 
ARA-C plus idarubicin,29’34 mitoxantrone plus 
etoposide,40 fludarabine plus ARA-C,22 or 
ARA-C, idarubicin plus etoposide29 have been 
tested. Results are summarized in Tables 1 
through 3. CR rates vary widely, ranging from
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15% attained by Kantarjian et al37 in 26 patients 
with myelodysplasia after previous cytotoxic 
therapy, to 61% reported by Michels et al48’49 in 
31 patients with refractory anemia with excess 
of blasts in transformation (RAEB-t) without 
previous exposure to leukemogenic chemicals. 
In smaller series, remission rates of up to 100% 
(6 CRs in 6 RAEB-t cases) have been reported.8
On average, CR rates of patients with MDS
' * 
appear lower than those of patients with de 
novo AML treated with either similar or identi-
4
cal chemotherapeutic regimens. This impres­
sion is supported by Fenaux et al,25 who reached 
CR rates of 71% in de novo AML and 48% in de 
novo MDS with an identical treatment protocol. 
However, the higher median age of MDS pa­
tients compared with AML patients may be at 
ieast partly responsible for the differences ob­
served. In patients younger than 45 years, De 
Witte et al obtained CR rates of 75% for de 
novo AML and 71% for MDS with an identical 
treatment protocol.16 Whether the CR rate is 
different in MDS and AML may also depend on
*
details of the treatment protocol used.
Reasons for the lower remission rates in 
MDS observed in some studies were (1) drug 
resistance of the neoplastic cell clone and (2) 
longer duration of the aplasia resulting in a 
higher early death rate. De Witte et al,16 Rich­
ard et al,57 and Fenaux et al24 have reported a 
longer duration of the pancytopenic period 
after completion of chemotherapy, resulting in 
toxic death rates of 14%, 22%, and 21%, respec­
tively. However, Tricot et al,63 Hoffmann et al34 
and Aul and Schneider8 failed to confirm a 
prolonged pancytopenic period in MDS pa­
tients treated aggressively.
In almost every instance, achievement of a 
CR is followed by complete hematologic recov­
ery and restoration of polyclonal hematopoi­
esis.36 However, duration of remission usually is 
short (Tables 1 through 3). Median remission
duration is less than 12 months, and remissions
i
exceeding 24 months are the exceptions to the 
rule. Overall survival rates were reported to be 
8% at 4 years after therapy at the Memorial 
Sloan-Kettering Cancer Center (MSKCC)47 and
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Table 1. Results of Intensive Chemotherapy for Nonspecified Myelodysplastic Syndromes
Early Remission Previous
Induction Patients CR Deaths No Duration Median Age Secondary Low-Dose
References Therapy (n) (n) in) Remission {mo) (Range) MDS ARA-C
De Witte16 AML 14 9 2 3 4 X  BMT, 5 
relapses (4-11 
mo)
42 (27 to 58) 1 0
Fenaux25 AML 31 17 Median 9 
months
54 (18 to 68 ) 0 0
Richard57 High-dose
ARA-C
1 0 1 0 ---------- 66 ----------:
Mertelsmann47 AML 31 14 ■---------- ---------- 8 % survival/4 
yrs
54 0 0
Kantarjian37 AML 26* 4 ---------- 26 —
Michels48,49 AML 8 3 ---------- 5 ---------- 8 0
LeBeau43 TAD 2 0 ---------- 2 68, 7 4 2 0
Aul7 AML 76 48 11 17 23% disease- 
free survival/5 
years
*Low-dose ARA-C was given to 12 of 112 patients.
Abbreviations: TAD, thioguanine, ARA-C, anthracycline; AML, various AML type chemotherapeutic regimens.
7% after 3 years in the report by De Witte et 
al.16 The relapse-free survival rate was 25% and 
0% in patients with normal or abnormal karyo­
types, respectively, in the report of Fenaux et 
al.24'26
THE FRENCH-AMERICAN BRITISH 
CATEGORIES OF THE MDSs
Because the MDSs comprise an extremely 
heterogeneous group of disorders, the question 
arises whether response rates after aggressive 
chemotherapy are different for the various types 
of MDS. At present, this question cannot be 
adequately answered because of the scarcity of 
data on results of chemotherapy in refractory 
anemia (RA), refractory anemia with ringed 
sideroblasts (RARS), and chronic myelomono- 
cytic leukemia (CMML). Almost all data on 
chemotherapy for MDS have been obtained in 
patients suffering from RAEB and RAEB-t. 
For these two categories results of aggressive 
therapy are given in Tables 2 and 3.
For CMML only the MSKCC47 and the M.D. 
Anderson Cancer Center in Houston22 have 
published data on a relevant number of cases. 
They obtained 9 CRs in 14 patients (MSKCC) 
and two CRs in seven patients (M,D. Ander­
son) treated aggressively. Data on peripheral 
blood leukocyte counts in those patients are 
lacking. Whether the patients represented 
CMML cases of myeloproliferative or myelodys­
plastic nature has not been stated.11«65
For RA and RARS, some case reports have 
been published. Estey et al22 have achieved CRs 
in six of nine patients treated with fludarabine 
administered in combination with ARA-C plus 
granulocyte colony-stimulating factor (G-CSF) 
in five patients.
Overall, treatment outcome is rather poor for 
any MDS category compared with data ob­
tained in AML. However, the question arises if 
this difference still exists when prognostically 
favorable cases of AML characterized by inver­
sion 16, translocation 8;21 or translocation 15;17
Table 2. Results of Intensive Chemotherapy for RAEB
References
Induction
Therapy
No. of 
Patients CR
Early
Deaths
No
Remission
Remission
Duration
(mo)
Median Age 
(Range)
Secondary
MDS
Previous
Low-Dose
ARA-C
Fenaux24 Rubida2one 2 1 1 0 2 + 39 ,58 0 0
Richard57 High-dose
ARA-C
1 0 0 1 50 0 0
Tricot63 AD, high-dose 
ARA-C
3 3 0 0 8, 13 +  BMT 4, 24, 28 1 0
AD, ARA-C, daunorubicin.
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Table 3. Results of Intensive Chemotherapy for RAEB-t
Remission Previous
No. Early No Duration Median Age Secondary Low-Dose
References Induction Therapy Patients CR Deaths Remission (mo) (Range) MDS ARA-C
Aul8'9 TAD 6 6 0 0 223+, 5, 29. 36+ 52 (17 to 57) 0 0
Fenaux24 RA 16 9 4 3 1 +, 2, 4. 5, 5 ,9  +  , 
13, 25+ , 28
47 (18 to 65) 0 0
Richard57 High-dose ARA-C 1 0 1 0 —■ 69 0 0
Michels49 AML 31 19 — 12 14 relapses 44 (?) 0 0
Tricot03 High-dose ARA-C 6 3 3 0 11, 12, 12 64 {40 to 78} 2 0
Scoazec60 AML 5 4 1 0 11,24, 27, 32 27 (18 to 56) 0 ' 0
Armitage6 AML 2 1 1 — 37+ 34, 38
Estey22 FLA(G) 2 1 1 — 37+ 34, 38
Abbreviations: TAD, thioguanine, ARA-C, anthracycline; RA, rubidazone; AML, various AML type chemotherapeutic regimens;
FLA(G), fJudarablne, ARA-C, plus or minus G-CSF.
are excluded. For AML patients remaining 
after exclusion of these categories, long-term 
event-free survival is less than 20%.22 If AML 
and MDS patients with prognostically unfavor­
able cytogenetic markers are compared, the 
difference between both categories is consider­
ably smaller or may even be absent.22
PROGNOSTIC FACTORS IN CHEMOTHERAPY
FOR MDS
In view of the divergent results of aggressive 
therapy for MDS, prognostic factors for re­
sponse to intensive chemotherapy must be iden­
tified. Patient age less than 45 to 50 years is a 
well-established prognostic factor after aggres­
sive therapy for MDS, as shown by Armitage et 
al,6 Tricot and Boogaerts63 (less than 50 years, 
86% CR; greater than 50 years, 25% CR), 
Michels et al48»49 (less than 45 years, 77% CR; 
greater than 45 years, 43% CR), and Gajewski 
et al. (less than 47 years, 77% CR; greater than 
47 years, 58% CR).28
Reports on aggressive chemotherapy in MDS, 
as shown in Tables 1 through 3, are almost 
entirely restricted to de novo cases. Thus, a 
direct comparison of treatment outcome in de 
novo and secondary cases of MDS is impossible. 
In secondary MDS, Kantarjian et al37 obtained a 
CR rate of 15% with AML-type chemotherapeu­
tic regimens, and Michels et al48,49 obtained 
three CRs in eight patients. Overall, these data 
as well as the scarcity of data on therapy in 
secondary cases of MDS do suggest that a prior 
exposure to leukemogenic cytostatic agents is a 
poor prognostic factor for success of aggressive 
chemotherapy in MDS.
Cytogenetic analysis has become an increas­
ingly recognized tool in the primary diagnosis 
of hematologic malignancies. The importance 
of this technique is underlined by the data of 
Fenaux et al,25’26 who obtained CRs in 57% of 
MDS patients with normal kaiyotypes, contrast­
ing with 31% CRs in 13 patients with rearrange­
ments or monosomies of chromosomes 5 and/or
7, and three CRs in six patients with other single 
chromosomal rearrangements. CRs of patients 
with abnormal karyotypes were extremely un­
stable, with patients relapsing within 5 months. 
In contrast, 25% of the patients without cytoge­
netic abnormalities remained relapse-free 3 
years after therapy. Similar data on the prognos­
tic significance of aberrations of chromosomes 5 
and 7 in aggressively treated patients have been 
provided by Fenaux et al23 as well as by the 
M.D. Anderson group22’37 in 72 patients with 
therapy-related MDS and AML (4 of 31 CRs 
versus 7 of 13 CRs in patients with normal 
karyotypes). De Witte et al16 and Tricot and 
Boogaerts,63 however, did not observe differ­
ences in remission rates relative to the presence 
or absence of chromosomal aberrations. The 
presence of Auer rods may imply a better 
prognosis.8,23,59
CHEMOTHERAPY AFTER CONVERSION TO
ACUTE LEUKEMIA
More than 50% of the patients suffering from 
MDS experience progression of the disease to 
frank leukemia. In view of the poor results of 
therapy in the myelodysplastic phase, the ques­
tion is whether one should withhold antileuke­
mic therapy until progression to frank leukemia. 
Table 4 gives an overview on results of aggres­
sive therapy for AML after a preceding myelo-
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Table 4. Results of Intensive Chemotherapy for AML after a Preceding MDS
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Previous
No. of Early No Remission Duration Median Age Secondary Low-Dose
References Induction Therapy Patients CR Deaths Remission (mo) (Range) AML ARA-C
A ul8'9 TA D 13 6 2 5 9, 1 +  , 5, 4 + , 23, 5 55(32 to 65) 0 5
Fenaux24 RA 9 4 4 1 6, 11+, 14, 42 + 55 (23 to 68 ) 0 0
Fenaux25 RA 16 5 — - — Median 10 
months
54 (18 to 6 8 ) 0 —
De Witte16 AML 15* 13 2 7 11 relapses (2 to 
25 mo)
47 (26 to 65) 7 0
Mertelsmann47 AML 16 5 --- --- 56 0 0
Keating38 ROAP 32 7 --- ---
Preisler54*55 High-dose ARA-C 11 2 7 2 More than 50 
years
Pedersen-Bjer- AML 3 0 --- —
gaard53
Gajewski28 TAD 44 18 9 17 17% DSF/3 years 59 (18 to 76) 3 0
Richard57 AML 6 6 0 0 2, 9, 10,12, 15+, 
19
59 {32 to 71) 0 0
Tricot63 High-dose ARA-C 3 2 1 0 BMT, BMT 27, 34, 67 —
Tallman02 AML 10 2 --- 3 --- 1
Hoyle35 TAD 36 15 9 12 2+, 2+ , 4, 4, 5, 5, 
5, 5 ,8 + ,  9, 35 +  , 
21, 15+, 13+,
19 +  , 20 +
61 (18 to 79)
Knauf40 NOVE 21 12 2 8 7 (2 to 10 mo) 56 (28 to 67) 0
LeBeau43 AML 10 1 4 5 57+ 51 (28 to 67) 10 0
*5 patients with MDS, but after chemotherapy.
Abbreviations: TAD, thioguanine, ARA-C, anthracycline; RA, rubidazone, ARA-C; AML, various AML type chemotherapeutic 
regimens; ROAP, rubidazone, ARA-C, vincristine, prednisone; NOVE, mitoxantrone and etoposide; DSF, disease-free survival.
dysplastic syndrome. The CR rate of the studies 
summarized in Table 4 is 37% in 231 patients. 
As can be derived from the table, some groups 
have treated patients in either phase of the 
disease and have received lower CR rates and 
poorer long-term results in those patients in 
whom treatment was started after conversion of 
the disease to overt leukemia.
TRANSPLANTATION OF
HEMATOPOIETIC CELLS
Allogeneic Bone M anvw Transplantation
Given the poor results of other treatment 
modalities with curative potential, allogeneic 
bone marrow transplantation (BMT) is the 
treatment of choice for younger patients with 
MDS who are lucky enough to have a histocom- 
patible sibling donor. The first cases of success“ 
ful marrow transplants in MDS patients have 
been reported more than 10 years ago.4,12,15,32 
Meanwhile, several larger BMT series of adult 
patients from single centers or registries have 
been published.1*2,3,5,20,45,46,50,51,56,61 *64 Table 5 sum­
marizes studies that encompass results of alloge­
neic BMT in 20 or more patients with MDS, 
Transplant data for children with MDS are still 
relatively scarce10,14,31 reflecting the fact that 
MDS in children is rare.33
The results of treatment with allogeneic BMT 
vary considerably depending on the subtype of 
disease at the time of transplantation and vari­
ous other clinical factors such as the presence of 
cytogenetic abnormalities,20,46 age,1,2 and the 
percentage of blasts in the bone marrow at the 
time of transplantation.1,2,51 For that reason, 
different disease categories and their influence 
on treatment outcome after BMT are discussed 
below; other factors found to be of significant 
importance in the major studies are listed in 
Table 5.
RA and RARS
Patients with RA and RARS are generally 
considered good candidates for BMT. Trans­
plant-related mortality is relatively low, relapses 
of the underlying disease are surprisingly rare, 
and disease-free survival usually exceeds 
50%.1,2’20 Patients with RA and RARS as well as
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Table 5. Results of BMT in Patients With MDS
Degree of Disease
Histocom­ Subtype Preparative Prognostic
Median patibility Pre-BMT Regimen Treatment- Disease- Factors)
References No. of Age (No. of (No. of (No. of Related No. of free for
(Year) Patients (Yr) Patients) Patients) Patients) Deaths Relapses Survival Survival
Marmont46 123 0 to 9 {7) ID ail RA (16) TBl + CHEMO nm -chromosomal
(1990) 10 to 39 (89) 
> 40  (27)
RAEB
RAEB-t
CMML
Other
(51)
(35)
(6)
(15)
(92)
BUS + CY (31)
134 ± 16%]b
at 2 yrs
[33 ±  11%]c 
at 2 yrs
abnormalities
Anderson2 93 30 (range, ID 64 RARS 29 CY + (F)TBI (88) 37 (40%) 18 (19%) 38 pts (41%) +youngerage
i 1995) 1 to 60) Twin 3 RAEB 31 BUS + CY (5) [44%]aat5yrs [29%]b at 5 yrs median 6.1 yrs -♦-shorter disease
MM 20 RA£B-t 14 (40%]c at 5 yrs duration
MUD 6 CMML
Other
2
17
-RAEB, RAEB-t 
-secondary 
MDS
Sutton61 86 35 (range, ID (84) RA 20 TBl + CHEMO (53) 30 (35%) 20 (23%) 33 pts (38%) +RA, RAEB,
<1991) 9 to 55) RAEB
RAEB-t
sAML
Other
26
18
17
5
BUS + CY (27) [37%]b median 28 mos 
{35.2%]c at 30 
mos
RAEB-t with 
stable disease 
+ untreated dis­
ease (for 
RAEB-t, sAML 
only)
De Witte20 78 32 ID 74 RA 9 TBl +  CHEMO 25 (32%) 18 (23%) 35 pts (45%) +CR after inten­
(1990) Twin 3 RAEB 16 (69) 2-91 mos sive chemo­
MM 1 RAEB-t
sAML
CMML
20
32
1
CHEMO (9) [RA 58%]c 
[RAEB 74% ]c 
(RAEB-t 50% ]c
therapy for 
sAML,
+ RA, RAEB, 
RAEB-t
Ubertf64 32 33 ID (21) RARS 9 BUS + ARA- 13 (39%) 2 (6%) 19 pts (59%) Non-ID marrow
(1994) MM
MUD
(6)
(5)
RAEB-t
Other
21
2
C + CY (29) 
BUS + TLI (2 
with FA) 
BUS + CY (1)
[12%]h median 24 mos 
[52%]c
donor
Nevill50 23 35 (range, ID (22) RA 2 BUS + CY 2 (22) 10 (43%) 5 (22%) 8 pts (35%) Younger age
(1992) 18 to 55) MM 0 ) RAEB
RAEB-t
CMML
Other
2
13
1
5
BUS + CY 4 (1) ]35%]b median 27 mos 
(35% 1° at 3 yrs
Longmore45 23 23 ID 21 RA 6 ARA-C, 9 (39%) 4 (17%)d 10 pts (43%) T-cell depletion
(1990) Twin 1 RAEB 6 CY + FTBI (13) [Primary MDS plus marrow
MM 1 RAEB-t
sAML
5
6
CY +  FTBI (5) 
CVB (3)
BUS + CY (1)
66%]°
[sMDS/sAML
27%]c
fibrosis
O'Donnell51 20 36 ID 19 RAEB 4 ARA-C, CY + TBl 9 (45%) 4 (20%) 7 pts (35%) (1 > 10% blasts in
(1987) Twin 1 RAEB-t
sAML
CMML
Other
8
1
2
5
(4)
FTBI + CY (3) 
(F)TBt + VP16 (7) 
TBl (3 Gy), BUS, 
VP16 (1)
BUS -f CY (5)
additional pt 
disease-free 
>1 year after
second BMT) 
3-110 mos
BM
Abbreviations: BMT, bone marrow transplant; ID, genotypically identical sibling donor; twin, identical twin; MM, family donor mismatched for 1-3 antigens; 
MUD, matched or partially mismatched unrelated donor; RA, refractory anemia; RAEB-t, RA with excess of blasts (In transformation); CMML, chronic 
myelomonocytic leukemia; sAML, AML developing from prior MDS or AML; NIM =  not mentioned; TBl, total body irradiation; FTBI, fractionated total body 
irradiation; CHEMO, chemotherapy; BUS, busulfan; CY, cyclophosphamide; CVB, CY, VP-16, BCNU; FA, Fanconi's anemia.
«Product limit estimate for BMT-relaied deaths. 
bProduct limit estimate of relapse. 
cProduct limit estimate of disease-free survival.
dAn additional patient grafted for RA and Hodgkin's disease relapsed with Hodgkin's disease.
those with a clinical picture of severe aplastic 
anemia but with cytogenetic aberrations typi­
cally associated with MDS (such as monosomy 
7) must be prepared with an aggressive marrow- 
ablative regimen. A conditioning regimen con­
sisting of cyclophosphamide alone is not suffi­
cient to eradicate the malignant clone. Such 
patients are at high risk to experience persisting 
or rapidly reemerging disease.4 Because of the 
relatively low number of patients transplanted 
with RA and RARS, it is still impossible to 
assess the impact of most pretransplant vari-
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ables on the outcome of BMT. A multivariate 
analysis from Seattle showed that disease dura­
tion did not significantly influence overall or 
disease-free survival; however, transplant-re- 
lated complications were lower in patients trans­
planted early in the course of disease.1’3 There- 
fore, early transplantation—possibly within the 
first year after diagnosis—seems justified: this 
practice might help patients to avoid transplant- 
related complications resulting from iron over­
load or opportunistic infections contracted dur­
ing prolonged periods of pancytopenia.
RAEB and RAEB-t
Outcome of BMT in patients with RAEB or 
RAEB-t is less favorable than that found in 
patients with RA(RS). The main reason for this 
diiference is a substantially higher relapse rate* 
The disease-free survival curves are significantly 
lower than in patients with RARS.2 An early 
European Group for Blood and Marrow Trans­
plantation (EBMT) analysis had shown an actu­
arial disease-free survival of 74% for patients 
transplanted with RAEB and of 50% when the 
patient had RAEB-t.2() A later analysis showed 
a 3-year disease-free survival of 32% in 18 
patients transplanted for RAEB and 27% in 11 
patients transplanted for RAEB-t. Late re­
lapses occurred especially in patients with RAEB 
showing a relapse pattern that was similar to 
that of chronic myeloid leukemia after BMT. 
The actuarial relapse rate at 3 years in this 
particular group of patients was higher than 
50%.17 One of the recent analyses from Seattle2 
showed a comparable cumulative relapse risk of 
49% in 47 patients transplanted with excess of 
blasts. Half the relapses occurred more than 1 
year after BMT. Nevertheless, immediate BMT 
is the only therapeutic option with a chance of 
cure and patients should be encouraged to 
proceed to BMT as soon as possible.
CMML
Only a few patients with CMML have been 
treated with BMT.1’27’41,46,50’51 Again, allogeneic 
BMT is the only treatment modality offering a 
chance of cure to such patients; it must be 
stressed, however, that because of the scarcity 
of data comments on the probability of disease- 
free survival, relapse rate, and transplant-
related mortality after BMT for CMML seem 
premature.
Secondaty AM L
Most European transplant centers will con­
sider BMT for secondary AML (sAML) only 
after remission induction chemotherapy has 
been administered. This approach, however, 
has never been formally tested. The results of 
BMT as primary therapy appeared worse for 
patients with overt sAML as compared with 
those with RAEB-t. Prolonged disease-free sur­
vival can be expected in approximately 20% of 
patients transplanted for sAML.20 Some pa­
tients with hypocellular marrow who are particu­
larly unlikely to respond favorably to intensive 
chemotherapy have achieved prolonged disease- 
free survival after BMT without preceding 
chemotherapy.19 Therefore, immediate BMT 
should be considered for each patient with 
sAML whose poor general condition or prob­
lems associated with low blood counts (fever 
and bleeding tendency) do not preclude this 
approach.
Remission duration for patients treated with 
AML-type remission induction chemotherapy 
usually is short,6’18*25 especially if cytogenetic 
abnormalities were present at the time of diag­
nosis.25 Accordingly, BMT should be offered to 
such patients immediately after a complete or 
even a partial remission has been achieved by 
intensive chemotherapy. The 2-year disease- 
free survival in 16 patients transplanted in CR 
after chemotherapy was 60%.20 Patients with a 
partial response to intensive chemotherapy re­
sponded less well and showed a 2-year disease- 
free survival of 18% whereas none of those who 
either relapsed or were resistant to chemother­
apy survived BMT for 2 years or more.
»
Therapy-related M DS and AM L
The actuarial disease-free survival of 11 pa­
tients transplanted for therapy-related MDS/ 
AML was 27% compared with 56%  for 12 
patients who were transplanted for primary 
MDS. However, the two groups were not com­
pletely comparable because the number of pa­
tients with overt AML was five in the therapy- 
related group as compared with none in the 
group with primary MDS.45 All seven patients 
transplanted for overt AML secondary to
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Hodgkin’s disease died of multiorgan failure 
(four patients) or leukemia.58 Four patients 
with AML secondary to treatment for Hodgkin’s 
disease were transplanted in first CR. Two 
patients were alive and disease-free at the time 
of writing.30 The EBMT17 compared transplant 
results of 28 patients with therapy-related 
RAEB-t or AML with the results of 53 patients 
with de novo RAEB-t or AML evolved from 
MDS. The overall disease-free suxvival was 
identical, but the relapse rate was slightly higher 
in the therapy-related group.
Alternative Sources o f Hematopoietic Stem Cells
Transplants from unrelated marrow donors. 
Unfortunately, at least two thirds of patients 
young enough to be candidates for an allogeneic 
BMT lack a human leukocyte antigen (HLA)~ 
identical sibling donor. For some of these pa­
tients a partially matched family donor can be 
identified.13’56 With the growing number of vol­
unteer donors registered worldwide, allogeneic 
BMT from a closely or fully matched unrelated 
donor has become another realistic alternative. 
Although a probability of disease-free survival 
of 18 ± 14% at 2 years reported by Kernan et 
al39 for 32 patients grafted from unrelated 
donors was somewhat disappointing recent data 
on unrelated BMTs in children are more encour­
aging. Casper et al14 reported that five of nine 
patients survived 27 to 80 months posttrans­
plant with four of them staying in remission. An 
analysis of unrelated donor BMTs in children 
performed in Seattle included five children with 
MDS, three of whom relapsed, one patient died 
of transplant-related causes, and one patient 
was disease-free at the time of publication.10
Autologous BMT\ One-hundred fourteen re­
cipients of autologous marrow grafts who suf­
fered from MDS or AML. secondary to MDS 
have been reported to the EBMT. The overall 
survival at 2 years of the 79 patients trans­
planted in first CR was 39%, disease-free sur­
vival was 34%, the actuarial relapse rate was 
64%. Nineteen patients were transplanted for 
MDS which had not progressed to AML before 
autologous BMT. The actuarial disease-free 
survival at 2 years in these patients was 40% and 
the relapse rate 58%. Thirty-nine MDS patients 
had progressed to AML before chemotherapy 
and autologous BMT. Disease-free survival was
30% and the relapse rate 68%. Twenty-one 
patients were transplanted for MDS or AML 
which had developed after treatment with 
chemotherapy for other malignancies or autoim­
mune diseases. Actuarial disease-free survival 
of these patients was 36% and the relapse rate 
60%. Patients younger than 40 years had a 
significantly (P  = .004) better disease-free sur­
vival as compared with patients with age > 40 
years. The difference could be explained by a 
significantly higher relapse rate (72%) in the 
older age group as compared with the younger 
patients (59%) (P  = .05). Transplant-related 
mortality and death due to failure to engraft did 
not appear to occur more often than after 
autologous BMT for de novo AML. However, 
hematopoietic engraftment was slower despite 
a sufficient number of colony forming units- 
granulocyte macrophage (CFU-GM) col­
lected—a situation similar to that observed in 
de novo AML patients.42 The median time to 
engraftment was 37 days for white blood cells 
and 75 days for platelets in the first retrospec­
tive analysis of the EBMT on 17 autografted 
MDS patients.52 Laporte reported the results of 
autologous BMT with mafosfamide treated mar­
row in seven patients with AML after MDS. 
Hematopoietic engraftment was slow in these 
patients, too, but all of them engrafted except 
for one patient who died early of treatment- 
related causes. Two patients were alive and well 
10 and 28 months after autologous BMT.42 Six 
patients received autologous peripheral blood 
progenitor cells in a prospective study of the 
European Organization for Research and Treat­
ment of Cancer (EORTC) leukemia coopera­
tive group and the EBMT.19 Peripheral blood 
stem cells were collected during the recovery 
phase of the first consolidation course, G-CSF 
was used to mobilize peripheral blood stem 
cells. Preliminary data indicate that repopula­
tion after transplantation of peripheral blood 
stem cells was much faster as compared with 
autologous BMT.19
In summary, any patient suffering from MDS 
or secondary AML who is younger than 55 years 
should be offered an allogeneic BMT if an 
HLA-identical sibling or a closely matched 
family donor is available. The search for a 
matched unrelated marrow donor has become 
increasingly successful over recent years and
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may be particularly rewarding for children and 
younger adults. Most patients may benefit most 
from an early transplant as soon as the diagnosis 
is confirmed and a suitable donor has been 
identified. Delay of the transplant carries the 
risk of progression of the disease. Transplanta­
tion of patients with an elevated percentage of 
blast cells in the marrow, however, is associated 
with a higher failure rate mainly due to an 
increased probability of relapse after BMT. 
Delay of the transplant may be justified in a 
minority of RA or RARS patients without 
cytopenia or complex cytogenetic abnormali­
ties, without leukemic in vitro growth character­
istics and no need for erythrocyte or platelet 
transfusions. All patients including those with­
out excess of blasts should be conditioned with 
bone marrow ablative therapy rather than an 
immune suppressive regimen, such as cyclophos­
phamide alone. Total body irradiation has been 
included in most BMT conditioning regimens, 
but preparation with a combination of busulfan
and cyclophosphamide may produce similar 
results. The pattern of continued relapse in
r
RAEB and RAEB-t patients beyond 1 year is 
reminescent of chronic myelogenous leukemia. 
Whether more intensive conditioning regimens 
or intensive polychemotherapy prior to the 
transplant procedure would yield better results 
is unknown at present. Younger patients not 
eligible for an allogeneic BMT are candidates 
for new experimental strategies like an autolo­
gous marrow transplant within the frame of 
clinical studies. Recent reports demonstrating 
the presence of polyclonal hematopoietic pro­
genitors in mobilized peripheral blood of pa­
tients with MDS21 will promote the use of PBPC 
instead of bone marrow cells also in the setting 
of MDS. Besides the possibility of grafting a pa­
tient with normal hematopoietic progenitor cells 
PBPC should be able to substantially shorten 
the time to platelet and neutrophil recovery 
after myeloablative therapy and thus reduce the 
risk of transplant-related complications.
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